PMID: 15378135Sep 21, 2004Paper

Ximelagatran: a new antithrombotic option in atrial fibrillation

Journal of Cardiovascular Pharmacology and Therapeutics
William E Dager

Abstract

Treatment strategies in patients with atrial fibrillation typically involve pharmacologic or interventional invasive therapies to suppress the rhythm, control ventricular contraction rates, or prevent thromboembolic complications. Current therapies used for rhythm conversion in atrial fibrillation may have undesirable risks or side effects that limit this approach. Lifelong anticoagulation may be necessary to prevent the formation of thrombus in the left atrial chamber that can travel into the cerebral circulation to cause a stroke. Currently, warfarin is the most commonly prescribed anticoagulant for this purpose. Unfortunately, many patients with atrial fibrillation may not receive warfarin because of the difficulties in dosing and maintaining desirable target goals. The oral direct thrombin inhibitor ximelagatran has several pharmacologic properties that provide a unique and potentially desirable treatment option. Clinical studies have demonstrated that ximelagatran, administered in twice-daily doses of 36 mg, is non-inferior to warfarin for thromboprophylaxis against stroke or systemic embolism in atrial fibrillation. The pharmacology of ximelagatran and clinical trials with its use in atrial fibrillation is reviewed.

References

Oct 1, 1977·The American Journal of Cardiology·R C HintonC M Fisher
Nov 30, 1999·Annals of Internal Medicine·R G Hart, J L Halperin
Feb 7, 2001·Chest·J AnsellD Matchar
Feb 7, 2001·Chest·G W AlbersD E Singer
Mar 10, 2001·Stroke; a Journal of Cerebral Circulation·R G Hart, J L Halperin
Apr 10, 2002·Pharmacotherapy·Simon de Denus, Sarah A Spinler
Nov 2, 2002·Stroke; a Journal of Cerebral Circulation·Robert G HartLesly A Pearce
Dec 6, 2002·The New England Journal of Medicine·D G WyseUNKNOWN Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
Dec 6, 2002·The New England Journal of Medicine·Isabelle C Van GelderUNKNOWN Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group
Feb 14, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ulf G ErikssonDavid Gustafsson
Mar 15, 2003·Blood·Christian P KalbererAleksandra Wodnar-Filipowicz
Mar 28, 2003·American Heart Journal·Ewurabena SimpsonLouise Pilote
Apr 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bernd Clement, Katrin Lopian
May 13, 2003·Expert Opinion on Pharmacotherapy·Karen L Kaplan
May 14, 2003·Journal of the American College of Cardiology·Palle PetersenUNKNOWN SPORTIF II Investigators
May 14, 2003·European Journal of Clinical Pharmacology·Ulf G ErikssonDavid Gustafsson
May 21, 2003·Annals of Internal Medicine·Robert G HartUNKNOWN Stroke Prevention in Atrial Fibrillation Investigators
May 30, 2003·The Annals of Pharmacotherapy·William E Dager
Aug 19, 2003·The Annals of Pharmacotherapy·William E Dager, Richard H White
Sep 12, 2003·The New England Journal of Medicine·Elaine M HylekDaniel E Singer
Mar 18, 2004·Current Medical Research and Opinion·Kajs-Marie SchützerUlf G Eriksson
Apr 22, 2004·Lancet Neurology·Geoffrey A DonnanBrian R Chambers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Acute Stroke

A stroke occurs when blood supply to the brain is interrupted depriving the brain of oxygen and nutrients. This feed focuses cerebrovascular accidents including ischemic and paralytic stroke.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.